173 related articles for article (PubMed ID: 34550957)
21. Efficacy and Safety of Multilayer, Extended-Release Methylphenidate (PRC-063) in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder: A Laboratory Classroom Study.
Childress AC; Brams MN; Cutler AJ; Donnelly GAE; Bhaskar S
J Child Adolesc Psychopharmacol; 2020 Dec; 30(10):580-589. PubMed ID: 33090921
[No Abstract] [Full Text] [Related]
22. Dexmethylphenidate for attention deficit hyperactivity disorder.
Coury D
Expert Opin Pharmacother; 2009 Nov; 10(16):2679-85. PubMed ID: 19874250
[TBL] [Abstract][Full Text] [Related]
23. Methylphenidate transdermal system in attention-deficit hyperactivity disorder in children: A viewpoint by Raul R. Silva.
Silva RR
Drugs; 2006; 66(8):1127-8; discussion 1128. PubMed ID: 16789798
[No Abstract] [Full Text] [Related]
24. A new amphetamine oral suspension (Adzenys ER) for ADHD.
Med Lett Drugs Ther; 2018 Jun; 60(1549):e106-e108. PubMed ID: 29913476
[No Abstract] [Full Text] [Related]
25. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
26. An expert opinion on methylphenidate treatment for attention deficit hyperactivity disorder in pediatric patients with epilepsy.
Baptista-Neto L; Dodds A; Rao S; Whitney J; Torres A; Gonzalez-Heydrich J
Expert Opin Investig Drugs; 2008 Jan; 17(1):77-84. PubMed ID: 18095920
[TBL] [Abstract][Full Text] [Related]
27. Analysis of Growth Velocity in Children with Attention-Deficit/Hyperactivity Disorder Treated for up to 12 Months with Serdexmethylphenidate/Dexmethylphenidate.
Childress AC; Cutler AJ; Patel M; Oh C
J Child Adolesc Psychopharmacol; 2023 May; 33(4):134-142. PubMed ID: 37204277
[No Abstract] [Full Text] [Related]
28. Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR) in Preschool Children with Attention-Deficit/Hyperactivity Disorder.
Childress AC; Kollins SH; Foehl HC; Newcorn JH; Mattingly G; Kupper RJ; Adjei AL
J Child Adolesc Psychopharmacol; 2020 Mar; 30(2):58-68. PubMed ID: 32125903
[No Abstract] [Full Text] [Related]
29. [Priapism - side effect of methylphenidate].
Aktuelle Urol; 2014 Mar; 45(2):94. PubMed ID: 24700059
[No Abstract] [Full Text] [Related]
30. Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder.
Ross RG
Am J Psychiatry; 2006 Jul; 163(7):1149-52. PubMed ID: 16816217
[No Abstract] [Full Text] [Related]
31. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder.
McGough JJ; McBurnett K; Bukstein O; Wilens TE; Greenhill L; Lerner M; Stein M
J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):351-6. PubMed ID: 16768642
[TBL] [Abstract][Full Text] [Related]
32. A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder.
Pelham WE; Aronoff HR; Midlam JK; Shapiro CJ; Gnagy EM; Chronis AM; Onyango AN; Forehand G; Nguyen A; Waxmonsky J
Pediatrics; 1999 Apr; 103(4):e43. PubMed ID: 10103335
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
[TBL] [Abstract][Full Text] [Related]
34. WITHDRAWN: Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Epstein T; Patsopoulos NA; Weiser M
Cochrane Database Syst Rev; 2016 May; (5):CD005041. PubMed ID: 27228176
[No Abstract] [Full Text] [Related]
35. Sleep disturbances and ADHD medications.
Rostain AL
Curr Psychiatry Rep; 2007 Oct; 9(5):399-400. PubMed ID: 17915079
[No Abstract] [Full Text] [Related]
36. Methylphenidate transdermal system: In attention-deficit hyperactivity disorder in children.
Anderson VR; Scott LJ
Drugs; 2006; 66(8):1117-26. PubMed ID: 16789796
[TBL] [Abstract][Full Text] [Related]
37. [Methylphenidate double-blind trial: indication and performing].
Bliznakova L; Gerstner S; Schmidt MH; Becker K
Klin Padiatr; 2007; 219(1):9-16. PubMed ID: 17205427
[TBL] [Abstract][Full Text] [Related]
38. Aptensio XR--another long-acting methylphenidate.
Med Lett Drugs Ther; 2015 Jul; 57(1473):101-3. PubMed ID: 26204039
[No Abstract] [Full Text] [Related]
39. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study.
Jain U; Hechtman L; Weiss M; Ahmed TS; Reiz JL; Donnelly GA; Harsanyi Z; Darke AC
J Clin Psychiatry; 2007 Feb; 68(2):268-77. PubMed ID: 17335326
[TBL] [Abstract][Full Text] [Related]
40. An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder.
Groenman AP; Schweren LJ; Dietrich A; Hoekstra PJ
Expert Opin Drug Saf; 2017 Apr; 16(4):455-464. PubMed ID: 28277842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
